Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
ReGenTree, LLC · Neurotrophic Keratopathy
Phase 3
Recruiting
70
2025-12
Industry sponsor intelligence
ReGenTree, LLCClinical Pipeline.
Lead-sponsor view of ReGenTree, LLC's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 6
- Recruiting
- 1
- Active
- 0
- Completed
- 4
- Results posted
- 3
- Avg enrollment
- 295
Pipeline overview
Programs by phase and activity.
Velocity
ReGenTree, LLC trials by start year
Study start year · indexed snapshot
Development
Trials by phase
7phase labels
Early Phase 10
Phase 10
Phase 23
Phase 34
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Thymosin Beta-4 → | 6 | 0 | 3 | 4 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
ReGenTree, LLC · Dry Eye Syndromes · Dry Eye
Phase 3
Completed
700
2022-05
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
ReGenTree, LLC · Dry Eye Syndrome
Phase 3
Completed
601
2022-01
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
ReGenTree, LLC · Dry Eye Syndrome
Phase 2 / Phase 3
Completed
317
2019-10
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye
ReGenTree, LLC · Dry Eye Syndrome · Dry Eye
Phase 2
Completed
72
2015-07
Search sponsor records
All ReGenTree, LLC studies.
This page groups studies where ReGenTree, LLC is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
6 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT05555589Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2Dec 23, 2025NCT03937882Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3May 9, 2022NCT02974907Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2Jan 5, 2022NCT02597803Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1Oct 17, 2019NCT01387347Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry EyeJul 10, 2015NCT00598871A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal WoundsJul 8, 2015